[{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Reports Positive Interim Phase 2a Data in Orphan Disease Cutaneous T-cell lymphoma (CTCL) with Lead Asset VDA-1102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Presents High Efficacy in Multiple Solid Tumor Models for its Next-Generation Cancer Drug Candidate and Synergy with Standard-of-Care Treatment in Liver Cancer Organoids","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma to Conduct Phase 2b Study for Actinic Keratosis Therapeutic Candidate VDA-1102 with CentroDerm","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Reports in Vitro Results Showing VDA-1275 Compatible with Classical Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Vidac Pharma
VDA-1102 (tuvatexib) is a novel Hexokinase 2 modulator small molecule drug which is under phase 2 clinical development for the treatment of mycosis fungoides, a form of cutaneous t-cell lymphoma.
VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
VDA-1102 (tuvatexib) is a novel Hexokinase 2 modulator small molecule drug which is under phase 2 clinical development for the treatment of actinic keratosis.
VDA-1275 is a VDAC/HK2 interaction Modulator, small molecule drug, orally administered, which is currently being investigated for the treatment of solid tumor.